En cours
TIMPANI
To evaluate the impact on 3-month mortality of adding adalimumab, an anti-TNF agent, to standard treatment consisting of antituberculosis drugs and high-dose steroids in HIV-infected adults diagnosed with tuberculous meningitis (TBM)
Project Details
Principal Investigator
V. Machault
Duration
48 months
Sponsor
ANRS MIE
Study start
26 Jun 2023
Objectives
Main Objectives
To evaluate the impact on 3-month mortality of adding adalimumab, an anti-TNF agent, to standard treatment consisting of antituberculosis drugs and high-dose steroids in HIV-infected adults diagnosed with tuberculous meningitis (TBM)
Research Team
The research team has not yet been filled in for this project.
Collaborate with us
We are open to partnerships with international research institutions and doctoral students.
Research Request
Estimated response time: 3-5 business days.
Keywords
CLINICAL RESEARCH
OUR PROJECTS
COHORTE
